Figure 4From: Complementary pharmacokinetic measures to further define the profile of once-daily OROS hydromorphone ER during single-dose and steady-state dosing Time spent ≥50% Cmax for OROS hydromorphone ER and IR hydromorphone by subject. Panels show time spent ≥50% Cmax by subject after single dosing (a), and at steady state (b). Cmax, maximum plasma concentration; ER, extended-release; IR, immediate-release.Back to article page